San Diego, California, USA, April 6, 2026
Commercial-Scale Manufacturing Readiness Demonstrated
In a significant advancement for biologics manufacturing and CDMO capabilities, Bora Biologics has successfully completed its first 2,000-liter engineering scale-up run at its FDA-approved San Diego facility, marking a critical milestone in its $30 million expansion strategy. This achievement confirms the facility’s full operational readiness for commercial-scale biologics production, including integrated upstream, downstream, and quality systems validation.
The scale-up also included the trastuzumab biosimilar (TX05) process transition from 1,000L to 2,000L, demonstrating the site’s ability to support late-stage clinical and licensure-stage manufacturing programs. This milestone underscores Bora’s capability to deliver high-volume, GMP-compliant production, positioning the company as a reliable partner for global biopharma sponsors seeking scalable and inspection-ready manufacturing infrastructure.
Advanced Infrastructure Enables Scalable Bioproduction
The expanded San Diego facility is designed to support multi-product operations, with single-use bioreactor capacity ranging from 500L to 2,000L, and future scalability up to 5,000L configurations. The successful engineering run validates the facility’s robust process scalability, technology transfer capabilities, and cross-functional execution, ensuring seamless progression from clinical development to commercial manufacturing. The infrastructure includes redundant systems, optimized material and personnel flows, and commercial-grade quality controls, enabling efficient execution of Process Performance Qualification (PPQ) campaigns and Biologics License Application (BLA) readiness.
Advertisement
By completing validation ahead of client demand, Bora Biologics reduces technology transfer risks and accelerates timelines for sponsors entering Phase III trials and commercialization phases, reinforcing its position as a next-generation CDMO provider.
Integrated U.S. Manufacturing Strengthens Supply Chain
Bora Biologics’ capabilities extend beyond drug substance manufacturing, with integrated fill-finish operations through Bora Pharmaceuticals’ FDA-approved facility in Baltimore, Maryland, offering a fully domestic end-to-end biologics manufacturing solution. This integrated model enables sponsors to streamline bulk production, sterile fill-finish, and final packaging within the United States, enhancing supply chain resilience and regulatory compliance.
As highlighted in the announcement, shifting global trade dynamics and tariff considerations are driving increased demand for U.S.-based biologics manufacturing capacity, making Bora’s infrastructure strategically valuable. The company’s ability to provide coordinated drug substance and drug product capabilities positions it as a preferred partner for biopharma companies seeking secure and scalable manufacturing solutions.
Supporting Biopharma Growth and Commercial Launches
With over 100 successful cGMP manufacturing batches and a proven track record in biologics development, Bora Biologics continues to expand its role in supporting global biopharmaceutical innovation. The validated 2,000L scale-up capability enables the company to support clients across key milestones, including Phase III trials, BLA submissions, PPQ execution, and commercial launch readiness. The recent TX05 resubmission filing further demonstrates the facility’s regulatory maturity and readiness for inspection, reinforcing confidence in its manufacturing systems.
By investing in infrastructure, scalability, and quality systems ahead of demand, Bora Biologics is positioning itself at the forefront of biologics manufacturing transformation, enabling faster, more reliable pathways from drug development to market commercialization. This milestone reflects a broader industry trend toward high-capacity, flexible, and regionally secure manufacturing ecosystems, critical for meeting the growing global demand for biologics therapies.
Source: Bora Biologics press release
